Mesenchymal Stem Cells (MSCs) Market By Donor Type (Allogeneic, Autologous); By Tissue Source (Bone Marrow, Adipose Tissue, Umbilical Cord and Wharton’s Jelly, Dental Pulp, Others); By Offering (MSC Therapeutic Products, Research-Use Cells and Culture Media, Cell Banking and Cryopreservation, Potency Testing and Analytical Services, Contract Development and Manufacturing Services); By Application (Graft-versus-Host Disease and Immune Disorders, Orthopedic and Cartilage Disorders, Wound Healing, Neurological Disorders, Cardiovascular Diseases, Oncology, Others); By End User (Hospitals and Transplant Centers, Academic and Research Institutes, Biotechnology and Pharmaceutical Companies, Contract Development and Manufacturing Organizations); By Geography, Segment Revenue Estimation and Forecast, 2026–2032.

Mesenchymal Stem Cells Market: Ryoncil Revenue, Trial Attrition, and Manufacturing Scale Redefine Competition

The Global Mesenchymal Stem Cells (MSCs) Market is projected to grow from USD 150 billion in 2025 to USD 754.61 billion by 2032, expanding at a strong CAGR of 25.96%, according to Strategic Market Research.

 

The Mesenchymal Stem Cells Market is primarily a biologic-therapy opportunity, but most current revenue is generated before a product reaches patients. Cell lines, culture media, potency assays, clinical-trial manufacturing, cryopreservation, analytical testing, and contract development account for a substantial share of spending.

 

Ryoncil became the first FDA-approved mesenchymal stromal cell therapy in December 2024. Mesoblast subsequently reported USD 115 million in Ryoncil net revenue for the year ended June 2026, including USD 36 million in the fourth quarter. The result provides stronger evidence of market formation than the number of experimental indications or registered studies. It shows that an MSC product can generate material revenue when regulatory approval, reimbursement, specialist-centre access, and reliable manufacturing are established together.

 

MSC research activity is much broader than commercial adoption. Searches have identified more than 1,760 MSC-related study records covering over 920 conditions, while the World Health Organization has reported more than 1,000 registered MSC trials. These figures include studies with different recruitment statuses, designs, and levels of evidence. They measure scientific activity rather than the number of products approaching approval.

 

Ryoncil Establishes the First U.S. Commercial Benchmark

The FDA approved Ryoncil, or remestemcel-L-rknd, on December 18, 2024, for children aged two months and older with steroid-refractory acute graft-versus-host disease. It is an allogeneic product manufactured from bone marrow-derived MSCs.

The supporting study enrolled 54 pediatric patients. At day 28, 70% had achieved an overall response. Complete responses accounted for approximately 30%, while partial responses accounted for approximately 41%. The median response duration was 54 days. These results were sufficient to establish clinical benefit in a severe condition with limited treatment options.

Ryoncil’s early commercial performance shows how an MSC therapy can overcome the limitations of a small eligible population. Mesoblast initially concentrated sales activity around transplant hospitals rather than attempting a broad pharmaceutical launch. By the first half of fiscal 2026, the company reported that 49 transplant centres had been onboarded. Its target of 64 centres would cover approximately 94% of U.S. transplant activity relevant to the product.

This concentrated buyer base reduces the cost of market access. A relatively small account team can reach most eligible patients. It also creates a demanding adoption process because each hospital must establish pharmacy handling, cryogenic storage, reimbursement procedures, clinical protocols, and repeat ordering arrangements.

Payer access has expanded alongside hospital coverage. Mesoblast reported reimbursement access covering approximately 280 million U.S. lives. CMS also established the permanent HCPCS code J3402 for remestemcel-L-rknd. The code gives hospitals a specific billing route for each therapeutic dose and reduces the administrative uncertainty that often slows adoption of newly approved biologics.

The initial course consists of eight intravenous infusions administered over four weeks at 2 million cells per kilogram of body weight. This schedule creates repeat product demand from each treated patient. It also raises the operational burden on transplant centres because product availability, authorization, storage, and administration must be coordinated eight times during the initial treatment period.

Mesoblast reported that 84% of early real-world patients completed the initial 28-day regimen and were alive at the end of that period. This is company-reported launch evidence rather than a controlled comparative result. Even so, treatment completion is commercially relevant because incomplete courses would reduce revenue per patient and weaken hospital confidence in stocking the product.

 

Adult Expansion Could Multiply Ryoncil’s Addressable Base

Ryoncil’s current label covers pediatric patients, but the adult steroid-refractory acute GVHD population is estimated by Mesoblast to be approximately three times larger. The company has aligned the Phase 3 adult protocol with the Blood and Marrow Transplant Clinical Trials Network, an NIH-supported clinical research network.

This collaboration improves access to experienced transplant centres and reduces the execution risk associated with recruiting a dispersed, critically ill population. It could also shorten the commercial ramp after approval because participating centres would already understand the treatment protocol and product-handling requirements.

An adult indication would allow Mesoblast to extend the same manufacturing platform, reimbursement infrastructure, distribution network, and hospital accounts across a larger population. This is more economically attractive than launching an unrelated MSC product that requires a new clinical pathway.

The expansion strategy also shows where near-term MSC revenue is most likely to emerge. Developers are prioritizing severe immune-mediated diseases with measurable short-term outcomes and centralized specialist care. These characteristics support premium biologic pricing and make treatment effects easier to demonstrate than in slowly progressing musculoskeletal or neurological conditions.

 

Commercial Revenue Is Funding Platform Expansion

Mesoblast reported USD 51.3 million in total revenue during the first half of fiscal 2026, compared with USD 3.2 million in the corresponding prior period. Ryoncil contributed USD 48.7 million in net revenue, while gross profit reached USD 44.2 million.

The high reported gross-profit contribution gives Mesoblast greater capacity to fund indication expansion, post-market activities, and manufacturing without relying entirely on new equity. This improves its strategic position relative to clinical-stage MSC developers that must repeatedly raise capital before generating product revenue.

In March 2026, the company drew USD 50 million from a five-year non-dilutive financing facility carrying an 8% fixed interest rate. The facility was secured against Temcell royalty income rather than Ryoncil or the company’s core intellectual property.

That structure preserves the option to license Ryoncil in additional territories or use its platform intellectual property in future partnerships. It also demonstrates that approved-product royalties can become financing assets, providing MSC companies with alternatives to shareholder dilution.

Mesoblast strengthened its technology position again in April 2026 by licensing Mayo Clinic-developed chimeric antigen receptor technology for MSCs. The platform is intended to improve the ability of cells to target specific inflamed tissue.

The transaction shifts competition beyond the basic expansion of naturally sourced MSCs. Engineered products could offer stronger tissue targeting, more measurable potency, and better intellectual-property protection. These features would help developers distinguish their therapies from the large number of minimally differentiated MSC programs.

 

Trial Volume Continues to Overstate Commercial Readiness

A 2023 review identified 1,120 registered MSC trials worldwide, but only 12 MSC therapies had obtained commercial approval at that time. Nine of those products were approved in Asia. South Korea accounted for five.

The gap between trial registrations and approvals is not a minor statistical issue. It reflects weak translation from early biological activity into reproducible clinical benefit. It also shows the difficulty of manufacturing living cells consistently across larger patient populations.

The approved-product count has changed since the review. Ryoncil entered the U.S. market, while Alofisel was withdrawn from the European Union. The historical count of 12 should therefore be used as evidence of low development productivity rather than as a current inventory of commercial therapies.

MSC programs also operate within a much larger cell-therapy pipeline. A recent analysis counted 10,373 registered cell-therapy trials worldwide. The United States accounted for 3,563, while China accounted for 3,365. These totals include immune-cell therapies, hematopoietic products, CAR-T programs, stem cells, and other somatic-cell treatments. They should not be presented as MSC trial counts.

A separate analysis identified 2,794 cell-therapy trials in China. The total included 2,045 immune-cell trials, 683 stem-cell trials, and 66 studies involving other somatic cells. MSCs accounted for a meaningful portion of the stem-cell pipeline, but more than half of the relevant studies were in Phase 1 or combined Phase 1/2 development.

China’s scale supports demand for research cells, media, clinical manufacturing, and testing services. Its early-stage concentration also means that near-term commercial product revenue will be much smaller than the trial count suggests.

 

Broad Multi-Disease Studies Add Research Volume, Not Product Validation

Study NCT04684602 evaluates stem-cell interventions across numerous disease cohorts. Its scope includes autoimmune, pulmonary, cardiovascular, neurological, metabolic, orthopaedic, and other conditions.

A broad protocol can improve research efficiency by using shared infrastructure and common safety procedures. It does not create one commercially validated multi-disease product. Each indication still requires a defined patient population, dose, endpoint, comparator, manufacturing process, and regulatory submission.

This distinction has direct implications for market forecasting. Counting every disease listed in a broad MSC study as an addressable therapeutic segment inflates demand. Cardiovascular injury, osteoarthritis, neurological disease, and immune disorders have different treatment pathways and reimbursement standards.

The most commercially attractive indications are those where a treatment can produce a measurable result within a practical trial period. Acute GVHD fits this profile because response can be evaluated quickly in specialist centres. Osteoarthritis provides a much larger patient pool, but products must show durable improvement against established injections, medicines, physical therapy, and surgery.

Neurological and cardiovascular programs carry even greater development risk. They often require larger trials, longer follow-up, and functional endpoints that may be affected by disease progression or background care. These requirements increase capital needs and delay revenue.

 

Cell Identity Is No Longer Sufficient for Regulatory Differentiation

The International Society for Cellular Therapy defines MSC populations partly through surface-marker expression. At least 95% of cells should express CD105, CD90, and CD73. No more than approximately 2% should express specified hematopoietic and immune-cell markers. The cells must also adhere to plastic and demonstrate bone, cartilage, and fat differentiation under laboratory conditions.

These criteria created a common language for research, but they are not a complete commercial release standard. Two batches can meet the same marker thresholds while producing different inflammatory, immune, or tissue-repair effects.

The strategic bottleneck has therefore shifted from confirming cell identity to measuring potency. Regulators increasingly expect developers to show that a laboratory assay reflects the biological function responsible for the clinical benefit.

This raises demand for flow-cytometry panels, cytokine assays, cell-viability systems, functional immune tests, reference materials, and contract analytical services. It also raises barriers to entry because a developer must connect its manufacturing controls with patient outcomes rather than rely on standard surface markers.

The WHO has worked toward an international reference reagent for MSC identity testing. Greater standardization would improve comparability between laboratories, but it could also expose products whose release specifications are weaker than industry benchmarks. Suppliers offering validated assays and reference materials are therefore positioned to benefit from tighter regulation.

 

Dose Requirements Directly Affect Manufacturing Economics

MSC clinical studies commonly use approximately 1 million to 4 million cells per kilogram, while some fixed-dose programs administer 100 million to 200 million cells. Ryoncil uses 2 million cells per kilogram per infusion, with eight infusions in the initial course.

These quantities influence far more than clinical protocol design. They determine how many patient doses can be produced from one donor bank, how much culture media is consumed, how long expansion takes, and how much final inventory must be stored.

Higher cell doses can increase the number of bioreactor runs and reduce batch availability. Repeated dosing also raises packaging, testing, shipping, and hospital-handling costs. Developers must therefore balance biological activity against the cost of producing and delivering each course.

The relationship is not always linear. A larger dose does not guarantee a stronger clinical response. Companies that identify an effective lower dose can improve gross margins and increase the number of commercial doses produced from each manufacturing batch.

This makes dose optimization a competitive advantage. It can lower cost of goods, reduce supply constraints, and make reimbursement discussions easier without changing the underlying cell platform.

 

Allogeneic Platforms Offer the Stronger Industrial Model

Allogeneic MSC products use cells from qualified donors to manufacture doses for multiple patients. The model allows companies to create master cell banks, test batches before release, maintain frozen inventory, and distribute standardized products to treatment centres.

Ryoncil, Temcell, and Cartistem demonstrate the commercial value of this approach. A centralized product can be ordered when needed, whereas patient-specific manufacturing requires collection, processing, scheduling, and release testing for each individual.

Autologous products may reduce some donor-compatibility concerns, but they are more difficult to scale. Variable patient material and individualized processing increase turnaround time and make manufacturing costs less predictable.

Tissue source still affects production economics. Bone marrow-derived MSCs have the longest clinical history, but donor age and invasive collection can limit starting material. Adipose tissue can provide higher initial cell yields. Umbilical cord and Wharton’s jelly cells offer strong expansion capacity and can be collected without an additional invasive donor procedure.

These characteristics influence batch size and cost, but no source is commercially superior in every disease. Changing the tissue source can alter potency, secreted factors, storage response, and clinical performance. A manufacturer cannot switch sources simply to lower costs without effectively changing the product.

 

Manufacturing Investment Is Building Capacity Ahead of Approvals

Cell-therapy companies are investing in larger production platforms before most MSC pipelines reach commercialization. OmniaBio opened a major cell and gene therapy manufacturing facility in Hamilton, Canada, in October 2024. The wider project represents more than CAD 580 million in investment and is expected to create approximately 250 skilled jobs.

The facility provides clinical and commercial manufacturing capacity for companies that cannot justify building their own plants. This is commercially important because dedicated cell-therapy sites require substantial capital, quality systems, specialist labour, and regulatory inspection readiness.

Medipost invested approximately USD 30 million to acquire an interest in OmniaBio and committed a further USD 60 million to the business in 2022. The investment links an established MSC product company with North American manufacturing infrastructure.

For Medipost, this creates a potential route to support international Cartistem expansion and offer third-party manufacturing services. It also reduces dependence on South Korean production as the company pursues larger regulated markets.

U.S. manufacturing contributed approximately USD 3.00 trillion, or 9.4% of national GDP, in the first quarter of 2026. It also accounted for approximately 52% of private-sector research and development activity. These figures do not measure MSC demand, but they indicate the financing, engineering, automation, and laboratory base available to advanced-biomanufacturing companies.

The stronger market signal is not manufacturing’s overall contribution to GDP. It is the increasing availability of GMP facilities that allow smaller MSC developers to progress without building their own commercial plants. This lowers the initial capital barrier but increases competition for validated capacity, technology-transfer slots, and experienced production staff.

 

Research Suppliers Are Moving Toward Bundled Cell-and-Media Platforms

NextCell Pharma and FUJIFILM Irvine Scientific launched NextCell-Cord globally in May 2026. The research-use product combines standardized umbilical cord-derived MSCs with FUJIFILM’s PRIME-XV culture medium.

The launch packages cells and media as one validated research workflow. This can reduce laboratory variability and shorten qualification work for biotechnology and academic customers. It also gives the suppliers recurring consumables revenue after the initial cell purchase.

NextCell stated that the launch was expected to have limited earnings impact during the first 12 months. That disclosure provides a useful market signal. Research-use products can reach customers faster than therapeutic products, but they usually generate smaller revenue per account and need broad distribution to become material.

Bundled platforms also strengthen supplier positioning. A customer that develops its early process around a particular cell source and culture medium may face additional comparability work if it changes suppliers later. Early research adoption can therefore influence future clinical-manufacturing purchasing decisions.

 

Asia Demonstrates Repeat Use, but Approval Does Not Protect Market Share

Medipost reported that Cartistem had been used in more than 30,000 patients by June 2024. The company also reported average annual sales growth of approximately 36% from launch through 2023. Cartistem became the first South Korean stem-cell therapy to exceed KRW 20 billion in annual sales.

These figures provide stronger evidence of repeat orthopaedic demand than clinical-trial registrations alone. Cartistem has built an established treatment history in knee cartilage defects associated with osteoarthritis, a much larger population than acute GVHD.

Medipost completed patient administration in a Japanese Phase 3 study involving 130 patients across 13 medical centres. The trial compares Cartistem with hyaluronic-acid treatment and includes 52 weeks of follow-up.

A successful Japanese filing would validate the product outside its home market. It would also create a benchmark for whether an MSC therapy can demonstrate sufficient benefit against a lower-cost and widely used orthopaedic intervention.

Medipost has also discussed licensing and partnership opportunities for international expansion. A regional partner could provide regulatory expertise, hospital access, reimbursement capability, and commercial infrastructure without requiring Medipost to build a full sales organization in each market.

JCR Pharmaceuticals’ Temcell generated approximately JPY 2.9 billion in sales during the fiscal year ended March 2025. Revenue declined 10.2% because competition intensified, although the product achieved the company’s plan. Temcell later recorded first-quarter sales of approximately JPY 845 million, representing growth of 15.8%.

The change in performance shows that regulatory approval does not create permanent market protection. Prescriber behaviour, alternative treatments, reimbursement, and hospital purchasing continue to influence mature MSC products.

 

Alofisel Changes the Risk Standard for Late-Stage MSC Programs

Alofisel was an allogeneic adipose-derived MSC product approved in Europe for complex perianal fistulas in adults with Crohn’s disease. Its original ADMIRE-CD trial enrolled 212 patients and showed a 15.8-percentage-point difference over placebo at 24 weeks.

The confirmatory ADMIRE-CD II study enrolled 568 patients. Combined remission occurred in 48.76% of Alofisel patients and 46.32% of placebo patients, leaving a difference of only 2.37 percentage points. The study did not meet its primary endpoint, and secondary outcomes did not establish a statistically significant advantage.

Alofisel was withdrawn from the European Union on December 13, 2024 because its clinical benefit could not be confirmed. The withdrawal was not based on a newly identified safety problem. It followed the failure of the larger study to reproduce the original efficacy result.

The commercial implication extends beyond one product. Investors and partners are now more likely to discount small, single-country, open-label, or weakly controlled MSC studies. Programs with subjective endpoints or unusually high placebo responses will face greater scrutiny.

Developers must also plan confirmatory trials before launch economics are fully established. An approval based on limited evidence may create temporary revenue, but manufacturing investment and commercial spending can be lost if later results fail.

 

Europe Is Refocusing on Narrow High-Need Indications

RHEACELL and AOP Health entered a commercialization partnership in May 2025 for MSC therapies targeting epidermolysis bullosa and chronic venous ulcers. Two Phase 3 programs are part of the collaboration. AOP Health contributes commercial operations across more than 50 countries, while RHEACELL supplies the cell-therapy platform and clinical development expertise.

The partnership reflects a more disciplined European strategy. Epidermolysis bullosa has a clearly defined high-need population, while chronic venous ulcers impose repeated treatment and wound-care costs. Both areas provide measurable endpoints such as wound closure, healing time, recurrence, and treatment burden.

The arrangement also illustrates how smaller MSC developers can reduce commercialization risk. Rather than building regional sales, medical-affairs, regulatory, and reimbursement teams, they can partner with a company that already operates across target markets.

This model is likely to become more common. The cost of Phase 3 development and biologic manufacturing makes fully independent commercialization difficult for small MSC companies.

 

Rare-Disease Pathways Can Improve Development Economics

REPROCELL submitted a Japanese manufacturing and marketing application for Stemchymal in June 2026. The product is being developed for spinocerebellar ataxia and uses allogeneic adipose-derived MSCs.

The company holds exclusive Japanese commercialization rights and has also expanded its U.S. manufacturing capability. In 2026, REPROCELL opened a GMP-compliant cell-culture facility and introduced a master-cell-bank manufacturing service.

Stemchymal has received orphan-drug support in Japan. The framework can provide assistance covering up to 50% of eligible development costs, along with tax incentives and priority review.

These incentives improve the economics of pursuing smaller neurological populations. They reduce development expenditure and shorten the period before a regulatory decision. A narrowly defined orphan indication may therefore offer a more credible route to approval than a large but clinically heterogeneous market.

REPROCELL’s combination of product rights and manufacturing services also diversifies revenue. The company can earn service income from external developers while its own therapy is under review.

 

Extracellular Vesicles Are a Supplier Opportunity Before a Drug Opportunity

MSC-derived extracellular vesicles are being studied as cell-free carriers of proteins, lipids, and genetic material. China and the United States account for a large share of publications in this field, with research covering musculoskeletal, neurological, cardiovascular, respiratory, renal, and oncology applications.

The commercial case is based on the possibility of easier storage, more consistent dosing, and lower biological variability than living cells. These advantages have not yet been demonstrated at the level required for broad therapeutic approval.

Isolation methods, purity standards, potency assays, and dose measurements vary considerably between developers. As a result, the immediate revenue opportunity lies in research reagents, purification equipment, analytical testing, and process-development services.

Counting extracellular-vesicle research as approved MSC therapy revenue would overstate the market. The segment should be treated as an adjacent platform that could expand the addressable market if manufacturing and regulatory standards converge.

 

Market Outlook

The Mesenchymal Stem Cells Market is transitioning from research-led spending to selective therapeutic commercialization. Ryoncil’s USD 115 million first-year net revenue provides the clearest evidence that an MSC product can create a viable U.S. market. Its performance was supported by permanent reimbursement coding, payer access, specialist-centre concentration, and repeat dosing.

The wider pipeline remains inefficient. More than 1,760 MSC study records and over 1,000 WHO-reported trials have produced only a small number of approved therapies. Alofisel’s withdrawal confirms that even approved products can lose commercial value when larger studies fail to reproduce efficacy.

Near-term therapeutic revenue will concentrate in acute transplant complications, rare immune diseases, selected chronic wounds, and other indications with measurable outcomes. Osteoarthritis offers a larger patient base, but adoption will depend on superiority over lower-cost established treatments.

Manufacturing and research suppliers will continue to capture revenue regardless of individual trial outcomes. Culture media, potency assays, cell banks, cryopreservation, GMP production, and analytical testing are required across the development pipeline.

Longer-term competition will shift toward engineered MSCs and cell-free products. These platforms could improve targeting and manufacturing consistency, but their commercial value will depend on clinical proof rather than theoretical biological advantages.

 

Mesenchymal Stem Cells Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 150.00 Billion
Revenue Forecast in 2032	USD 754.61 Billion
Overall Growth Rate	CAGR of 25.96% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million, CAGR (2026–2032)
Segmentation	By Donor Type, By Tissue Source, By Offering, By Application, By End User, By Geography
By Donor Type	Allogeneic, Autologous
By Tissue Source	Bone Marrow, Adipose Tissue, Umbilical Cord and Wharton’s Jelly, Dental Pulp, Others
By Offering	MSC Therapeutic Products, Research-Use Cells and Culture Media, Cell Banking and Cryopreservation, Potency Testing and Analytical Services, Contract Development and Manufacturing Services
By Application	Graft-versus-Host Disease and Immune Disorders, Orthopedic and Cartilage Disorders, Wound Healing, Neurological Disorders, Cardiovascular Diseases, Oncology, Others
By End User	Hospitals and Transplant Centers, Academic and Research Institutes, Biotechnology and Pharmaceutical Companies, Contract Development and Manufacturing Organizations
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Commercialization of approved allogeneic MSC therapies, growing demand for GMP manufacturing and analytical testing, expansion of research-use cell and media platforms, rising investment in potency assays and engineered MSC technologies
Customization Option	Available upon request